Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance
Akoya Biosciences (Nasdaq: AKYA) reported a strong performance for Q3 2022, with revenues of $18.9 million, marking a 40% year-over-year increase. Product revenue rose to $14.4 million, up 32%, driven by a 67% increase in instrument sales with 55 units sold. The installed base has reached 863 instruments. Year-to-date revenue is $53.6 million, up 38%. Gross profit for the quarter was $10.9 million, maintaining a 58% margin. The company has raised its full-year revenue guidance to $73-75 million due to positive growth trends and strong market execution.
- Q3 2022 revenue increased 40% year-over-year to $18.9 million.
- Year-to-date revenue up 38% to $53.6 million.
- Product revenue rose 32% to $14.4 million in Q3 2022.
- Instrument sales grew by 67%, selling 55 units in Q3 2022.
- Maintained a gross profit margin of 58% in Q3 2022.
- Raised full-year revenue guidance to $73-75 million.
- None.
Q3 2022 revenue
Raising FY 2022 revenue guidance range to
MARLBOROUGH, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2022.
“Akoya continues to deliver strong financial performance with record growth this quarter and healthy system placement across the discovery, translational and clinical markets,” said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. “Our industry leading portfolio and installed base, commercial execution, and success across multiple market segments, from discovery to clinical, are key drivers of our success.”
Third Quarter 2022 Financial Highlights
- Total revenue was
$18.9 million in the third quarter of 2022, compared to$13.5 million in the prior year period; an increase of40% . - Product revenue was
$14.4 million in the third quarter of 2022, compared to$10.9 million in the prior year period; an increase of32% .- Instrument revenue was
$9.5 million , compared to$7.1 million ; an increase of34% . - Reagent revenue was
$4.7 million , compared to$3.4 million ; an increase of38% .
- Instrument revenue was
- Services and other revenue totaled
$4.4 million in the third quarter of 2022, compared to$2.6 million in the prior year period; an increase of69% . - Gross profit was
$10.9 million and gross profit margin was58% in the third quarter of 2022. - 55 instruments were sold in the third quarter of 2022; 17 PhenoCyclers, 38 PhenoImagers (which includes Fusion, HT and Mantra); compared to 33 instruments sold in the prior year period (16 PhenoCyclers, 17 PhenoImagers); an increase of
67% . - Instrument installed base of 863 as of September 30, 2022; 229 PhenoCyclers, 634 PhenoImagers.
- Combined-unit PhenoCycler-Fusion installed base of 72 as of September 30, 2022.
$82 million of cash, cash equivalents, and marketable securities as of September 30, 2022.
YTD 2022 Financial Highlights
- Total revenue was
$53.6 million YTD as of September 30, 2022 compared to$38.8 million in the prior year period; an increase of38% . - Product revenue was
$41.9 million YTD as of September 30, 2022, compared to$31.6 million in the prior year period; an increase of33% . - Services and other revenue totaled
$11.7 million YTD as of September 30, 2022, compared to$7.2 million in the prior year period; an increase of63% . - Gross profit was
$31.3 million and gross profit margin was58% YTD as of September 30, 2022. - 166 instruments were sold YTD as of September 30, 2022; 47 PhenoCyclers, 119 PhenoImagers (which includes Fusion, HT and Mantra), compared to 101 instruments sold in the prior year period; an increase of
64% .
Third Quarter 2022 Business Highlights
- As of September 30, 2022, there have been 691 total publications featuring Akoya’s platforms;
81% growth from 382 total publications as of September 30, 2021. - At the upcoming Society of Immunotherapy of Cancer (SITC) conference taking place in Boston, MA (November 8-12, 2022), Akoya will unveil the PhenoCode Signature Panels (previously referred to as universal protein chemistry) on the PhenoImager workflows; please see the accompanying PhenoCode Signature Panels press release for more details.
- At SITC, 6 key posters will be presented highlighting the development of PhenoCode Signature Panels and other novel phenotyping applications; Akoya will also be hosting a dinner symposium titled “Supercharging Spatial Signature Development.”
- Akoya will be hosting our 2nd annual Spatial Day on December 15, 2022, for which registration details can be found here: Akoya’s 2nd Annual Spatial Day.
2022 Financial Outlook
The Company, based on its updated plans and initiatives, is raising its full year 2022 revenue guidance range to
Webcast and Conference Call Details
Akoya will host a conference call today, November 7 2022, at 5:00 p.m. Eastern Time to discuss its third quarter 2022 financial results. Investors interested in listening to the conference call are required to register online. A live webcast of the conference call will be available on the “Investors” section of the Company's website at https://investors.akoyabio.com/. The webcast will be archived on the website following the completion of the call for three months.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including expectations regarding our ability to market and sell our PhenoCycler and PhenoImager platforms and increase awareness of spatial biology technology, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences
investors@akoyabio.com
Media Contact:
Christine Quern
617-650-8497
media@akoyabio.com
AKOYA BIOSCIENCES, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets (unaudited)
(in thousands)
| September 30, 2022 | December 31, 2021 | |||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 51,836 | $ | 113,079 | ||
| Marketable securities | 29,868 | — | ||||
| Accounts receivable, net | 8,680 | 9,444 | ||||
| Inventories, net | 13,063 | 9,014 | ||||
| Prepaid expenses and other current assets | 8,297 | 9,277 | ||||
| Total current assets | 111,744 | 140,814 | ||||
| Property and equipment, net | 10,492 | 7,487 | ||||
| Demo inventory, net | 2,064 | 2,548 | ||||
| Intangible assets, net | 20,442 | 21,150 | ||||
| Goodwill | 18,262 | 18,262 | ||||
| Operating lease right of use assets, net | 11,307 | — | ||||
| Financing lease right of use assets, net | 1,504 | — | ||||
| Other non-current assets | 642 | 646 | ||||
| Total assets | $ | 176,457 | $ | 190,907 | ||
| Liabilities and Stockholders’ Equity | ||||||
| Current liabilities | ||||||
| Accounts payable, accrued expenses and other current liabilities | $ | 22,209 | $ | 23,198 | ||
| Current portion of operating lease liabilities | 3,004 | — | ||||
| Current portion of financing lease liabilities | 593 | — | ||||
| Deferred revenue | 5,876 | 4,484 | ||||
| Total current liabilities | 31,682 | 27,682 | ||||
| Deferred revenue, net of current portion | 1,477 | 1,330 | ||||
| Long-term debt, net | 52,714 | 32,471 | ||||
| Contingent consideration liability, net of current portion | 5,956 | 7,850 | ||||
| Operating lease liabilities, net of current portion | 8,723 | — | ||||
| Financing lease liabilities, net of current portion | 692 | — | ||||
| Other long-term liabilities | 125 | 223 | ||||
| Total liabilities | 101,369 | 69,556 | ||||
| Total stockholders' equity | 75,088 | 121,351 | ||||
| Total liabilities and stockholders' equity | $ | 176,457 | $ | 190,907 | ||
AKOYA BIOSCIENCES, INC. AND SUBSIDIARY
Consolidated Statements of Operations (unaudited)
(in thousands, except share and per share amounts)
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | 14,438 | $ | 10,874 | $ | 41,942 | $ | 31,556 | ||||||||
| Service and other revenue | 4,414 | 2,602 | 11,698 | 7,203 | ||||||||||||
| Total revenue | 18,852 | 13,476 | 53,640 | 38,759 | ||||||||||||
| Cost of goods sold: | ||||||||||||||||
| Cost of product revenue | $ | 5,455 | $ | 3,594 | $ | 14,733 | $ | 10,381 | ||||||||
| Cost of service and other revenue | 2,490 | 1,429 | 7,563 | 4,386 | ||||||||||||
| Total cost of goods sold | $ | 7,945 | $ | 5,023 | $ | 22,296 | $ | 14,767 | ||||||||
| Gross profit | $ | 10,907 | $ | 8,453 | $ | 31,344 | $ | 23,992 | ||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 19,922 | 13,725 | 58,705 | 31,970 | ||||||||||||
| Research and development | 5,466 | 3,999 | 16,778 | 10,138 | ||||||||||||
| Change in fair value of contingent consideration | 357 | 224 | (599 | ) | 1,050 | |||||||||||
| Depreciation and amortization | 1,815 | 1,244 | 4,975 | 3,352 | ||||||||||||
| Total operating expenses | 27,560 | 19,192 | 79,859 | 46,510 | ||||||||||||
| Loss from operations | (16,653 | ) | (10,739 | ) | (48,515 | ) | (22,518 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (1,109 | ) | (763 | ) | (2,707 | ) | (2,271 | ) | ||||||||
| Change in fair value of warrant liability | — | — | — | (2,728 | ) | |||||||||||
| Gain on extinguishment of debt | — | — | — | 2,476 | ||||||||||||
| Other expense, net | (89 | ) | (126 | ) | (395 | ) | (244 | ) | ||||||||
| Loss before benefit (provision) for income taxes | (17,851 | ) | (11,628 | ) | (51,617 | ) | (25,285 | ) | ||||||||
| Benefit (provision) for income taxes | (21 | ) | 11 | (149 | ) | 23 | ||||||||||
| Net loss | $ | (17,872 | ) | $ | (11,617 | ) | $ | (51,766 | ) | $ | (25,262 | ) | ||||
| Dividends accrued on redeemable convertible preferred stock | — | — | — | (1,435 | ) | |||||||||||
| Accretion of redeemable convertible preferred stock | — | — | — | (296 | ) | |||||||||||
| Adjusted net loss attributable to common stockholders | (17,872 | ) | (11,617 | ) | (51,766 | ) | (26,993 | ) | ||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.47 | ) | $ | (0.31 | ) | $ | (1.37 | ) | $ | (1.15 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 37,900,821 | 37,162,489 | 37,660,814 | 23,407,358 | ||||||||||||
FAQ
What were Akoya's (AKYA) Q3 2022 revenues?
What is Akoya's (AKYA) revenue guidance for FY 2022?
How many instruments did Akoya (AKYA) sell in Q3 2022?
What was Akoya's (AKYA) gross profit for Q3 2022?
What were the key highlights of Akoya's (AKYA) Q3 2022 earnings call?
